Five-Year Results of the Bioflow-III Registry: Real-World Experience with a Biodegradable Polymer Sirolimus-Eluting Stent
Highlights
- • Prospective international registry including 1738 Orsiro-treated lesions
- • Subgroups: diabetics, small vessels, chronic total occlusion, myocardial infarction
- • 5-year target lesion failure of 10.0% [95% CI: 8.4; 13.5] in the overall population
- • 5-year target lesion failure of 1.8% to 14.0% in subgroups
- • 5-year definite stent thrombosis ≤0.5% in the overall population and in subgroups
Abstract
Purpose
We aimed to assess long-term safety and performance of the Orsiro sirolimus-eluting coronary stent with biodegradable polymer in a large unselected population and in pre-specified subgroups.